Skip to main content
Premium Trial:

Request an Annual Quote

Cue Health Receives $481M From DoD to Expand COVID-19 Testing Capacity

NEW YORK – Cue Health announced Tuesday it has received a $481 million award from the US Department of Defense to expand its production capacity for COVID-19 tests.

The money will be used to help Cue onshore its supply chain and increase production capacity to provide 6 million of its point-of-care COVID-19 tests by March 2021. The test returns results within 20 minutes and runs on the Cue Health Monitoring System with a reusable cartridge reader and single-use test kits. The cartridge reader sends results directly to the Cue Health App, downloaded to a smartphone or other device, the company said.

The effort to expand capacity is led by the DOD's Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense in coordination with DoD's Joint Acquisition Task Force. The award is funded through the US Department of Health and Human Services' Office of the Assistant Secretary for Health to support domestic production of critical medical resources. Test cartridges will be manufactured at Cue's facilities in San Diego.

The Cue Health Monitoring System and Cue COVID-19 test received Emergency Use Authorization from the US Food and Drug Administration in June for use at the point-of-care as directed by healthcare providers. The firm also closed a $100 million Series C financing round in June to complete the development, validation, and manufacturing scale-up of the monitoring system and test cartridges. 

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.